BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang(Zhongshan People's Hospital), Shanzhi He(Zhongshan People's Hospital), Wenli Zhang(Peking University Shenzhen Hospital), Hongyu Zhang(Peking University Shenzhen Hospital), V. Destéfano(Io Therapeutics (United States)), M. Wada(Io Therapeutics (United States)), Kevin G. Pinz(Io Therapeutics (United States)), Greg Deener(Io Therapeutics (United States)), Darshi Shah(Io Therapeutics (United States)), Nabil Hagag(Io Therapeutics (United States)), Min Wang(Zhongshan People's Hospital), Ming Hong(Zhongshan People's Hospital), Ronghao Zeng(Zhongshan People's Hospital), Ting Lan(Zhongshan People's Hospital), Yu Ma(Io Therapeutics (United States)), Fugui Li(Zhongshan People's Hospital), Yingwen Liang(Zhongshan People's Hospital), Zhencong Guo(Zhongshan People's Hospital), Chanjuan Zou(Zhongshan People's Hospital), Mingxia Wang(Zhongshan People's Hospital), Ling Ding(Zhongshan People's Hospital), Yupo Ma(Io Therapeutics (United States)), Yong Yuan(Zhongshan People's Hospital)
Cited by 184